Health Economics for Non-Health-Economists

With Prof. Dr Lieven Annemans

Course Details

Pharma/medtech products cannot be successful without a favourable cost-effectiveness and budget impact profile.

Therefore, all managers in clinical development, regulatory, market access (and related), medical affairs, and marketing should understand the fundamentals of health economic evaluations and budget impact analysis.

Only then will they take product-related decisions that consider the payers’ perspectives and optimally communicate value to payers, KOLs and other external stakeholders.

Upon completion of this course, you will master the fundamentals of health economic evaluations as a non-health-economist. And you will be able to add value to decisions and communications related to products in R&D and/or brands in the market.

By participating, you will not only have the chance to learn from a renowned expert, but also experience the unique opportunity to share experiences and engage in in-depth discussions with your international peers. 
 

Hear directly from Lieven why you should attend this course:

I encourage anyone without prior knowledge of HEOR to take this course. You’ll not only gain an awareness of the topic but also feel more confident participating in HEOR discussions.

Chiesi

Caterina Barone, Global Pricing Senior Analyst - Global - March 2025

  1. The logic and mathematics behind QALYs, ICERs, decision trees and Markov models.

  2. How external stakeholders use and challenge health economic evidence.

  3. How to distinguish good from bad health economic evaluation studies (of your brand or its competitors).

  4. Key principles of cost-effectiveness analysis and Budget Impact Analysis.

  5. The role of health economic evaluations in clinical research, pricing & reimbursement decisions, and post-launch. 

Course agenda

 

The mystery of health economics has now been unravelled! Two valuable days well invested, and I now feel confident in demonstrating the cost-effectiveness of this investment of my time – I may even illustrate it using a model! Thank you.

Convatec Group

Shona Macdonald, Director Market Access & Reimbursement UK - United Kingdom - January 2025

 

 

Day 1
10:00Welcome & General Introduction
10:30Fundamentals of Health Economic Evaluations: QALY - ICER - HTA
 
  • Why health economic evaluations are necessary
  • Key principles of health economic evaluations
    • QALY: The mathematics – examples
    • Value for money: Balancing costs vs. health effect
    • The Incremental Cost-Effectiveness Ratio (ICER) and the thresholds determined by payers
    • Health economic evaluations vs. Health Technology Assessment (HTA)
11:45Coffee Break
12:00Health Economic Modelling – Commonly Used Models
 
  • Decision Trees
    • The logic of this model will first be explained with a simplified example
    • Real-world examples
  • Markov models
    • The logic of this model will first be explained with a simplified example
    • Real-world examples
  • Example of a Discrete Event Simulation
  • How to make models credible and reliable
  • When to use which model
13:15Lunch Break
14:00Cost Analysis and Budget Impact Analysis: Key Principles
 
  • The perspective of the study: Societal – Health Care Sector – Hospital
  • Impact of the perspective on costs and savings
  • How to deal with current benefits versus benefits in the future?
  • Budget Impact Analysis: Answering the question of affordability
15:30Coffee Break
15:45Prospective Research for Health Economic Evaluations (Includes a Group Exercise)
 
  • Conflicts between the clinical and the health economic perspective
  • Six practical steps for prospective “within-trial” health economic studies
  • Break-Out Session: “To HE or not to HE?”: Participants will discuss in groups the pros and cons of collecting health economic (HE) data directly into a phase III trial in the field of asthma.
  • Addressing the challenges of integrating clinical data in health economic evaluations
17:00Close Day 1
 
Day 2
09:00Recap of Day 1 With Exercises on QALYs & ICERs
09:45Guidelines for Health Economic Evaluations (Includes a Group Exercise)
 
  • What distinguishes a good from a poor health economic evaluation?
  • A 10-item checklist for a good health economic paper
  • How to increase the credibility of health economic messages in the value message?
  • Break-Out Session: In groups, participants will assess a health economic evaluation that has been shared as a pre-read using the 10-item checklist. Findings will be discussed in plenary. 
10:30Coffee Break
10:45Guidelines for Health Economic Evaluations (continued)
12:30Lunch Break
13:15Use of Health Economic Evaluations in Price & Reimbursement Decision Making
 
  • What is true innovation – the payer perspective
  • The secrets behind measuring the QALY and its limitations
  • The role of medical need
  • The role of budget impact
  • Dealing with uncertainty: Outcome-based managed entry agreements
14:30Health Economic Evaluations in a Pharmaceutical Drug’s Life Cycle
 
  • The importance and purpose of early economic models
  • Organisation and processes within HQ and affiliates
  • Post-launch and the use of real-world data
15:00Break-Out Session: Developing Together a Health Economic Strategy
 In groups, participants will design an early decision model (a decision tree) for a new medicine. They will assess which key pre-marketing data are needed to complete the health economic value story and how these data can be collected.
Group findings will be discussed in plenary.
Coffee Break will be served during break-out session
16:00Final Discussion
16:15End of Course

 

Download Brochure

 

What is the difference with the Online Self-study Programme Basics of Health Economics?

  • The 2-day face-to-face course has more breadth and depth in both theory (lectures) and practice (group work). For instance, the 2-hour module on the “Guidelines for Health Economic Evaluations” is highly valued because of the interactive group work session on a health economic publication.

  • In a face-to-face classroom training, you learn a lot from your industry peers because of the exchange of experiences and ideas and the discussions about issues you face in your function. The Q&A sessions are very rich and you will have many opportunities for conversations with your peers outside the formal programme. 

  • Participating in the 2-day course gives the opportunity to meet Prof. Dr Lieven Annemans and discuss your own projects/issues with him during the breaks. 

Complete the below form to download the full course brochure. It outlines the detailed agenda, learning outcomes, expert info and some testimonials from past participants.

  • Prof. Dr Lieven Annemans has participated in more than 400 health economic evaluations in over 20 countries across a wide spectrum of therapeutic areas. He has also been involved as an expert in a large number of Health Technology Assessments (HTAs) and is actively involved in HTA on a European level.

  • Lieven has a unique profile: academic professor, past-president of ISPOR, author of Health economics for non-economists (Pelckmans Pro, 2018), trainer and consultant.

  • Highly respected for his vast international and cross-therapeutic experience, Lieven is a sought-after advisor and educator to health policy makers and the innovative healthcare industry.

  • Lieven has been on CELforPharma's faculty since 2009 and is always applauded by participants for his engaging and fun teaching style.
     

This course fully lived up to my expectations—and more. I can't wait to put what we have learned into practice. Lieven is an excellent teacher.

LEO Pharma

Andreas Laursen, Global Pricing Principal - Denmark - March 2025

As the course title suggests, this course is designed for non-health-economists.

As pharma companies are facing ever-increasing hurdles to optimise market access for their brands, all managers in product development, medical affairs and marketing should attend this course so that they can contribute to a successful integration of health economic evaluations into clinical, medical and brand plans.

While most of the examples and exercises discussed in this course are about pharmaceuticals, this course is equally relevant to, and has always been highly valued by, executives from the medical devices industry.

Would you like to receive a list of anonymised participant profiles from previous sessions? 

Email Annelies Swaan

 

 

UPCOMING DATES & FORMATS - FEES

7-8 October 2025

Brussels

Early bird € 2 970

(until 22/08/2025)

(Full fee € 3 370)

25-26 November 2025

Brussels

Early bird € 2 970

(until 10/10/2025)

(Full fee € 3 370)

 

Dates don't suit or you do not have the possibility to travel to Brussels?

Check out our Online Self-Study Programme Basics of Health Economics with Prof. Dr Lieven Annemans.

 


TIMING & LOCATION

  • Live Online (CET): Zoom sessions between 9 AM and 5 PM CET (Brussels, Amsterdam, Paris time).

  • Live Online (EST): Zoom sessions between 8 AM and 4 PM EST (Eastern Standard Time).

  • Face-to-Face: Held at the Crowne Plaza Brussels Airport (Da Vincilaan 4, 1831 Brussels), between 9 AM and 5 PM CET. Preferential hotel rates available for participants.

All practical details will be shared upon registration. For any questions, please contact Margherita Mutto or call +32 472 03 11 38 .

 

GROUP DISCOUNTS

Team discounts can be offered to 2 or more delegates from the same company.

Email Annelies Swaan, Director Business Operations, for more details. 

 

HOW TO REGISTER

  • Click the green “Register” button on your preferred course session.
    The registration wizard will guide you through the process.

  • Alternatively, download the offline registration form and send the completed form to Annelies Swaan.

 

PAYMENT OPTIONS

  • Credit Card: You’ll receive a secure payment link with your invoice (no immediate payment required).

  • Bank Transfer: Details provided with your invoice.

For help with registration, email Annelies Swaan or contact her by phone at +32 486 98 52 49.

 

INCLUDED IN THE REGISTRATION FEE

  • Access to a highly interactive, small-group course (max 20 participants)

  • Course materials in both digital and hard copy format

  • Certificate of attendance signed by the experts and CELforPharma

  • Opportunities for networking and informal discussions during coffee/tea breaks and lunch

  • A group dinner in a nearby restaurant on the evening of day 1

 

VAT INFORMATION

Prices exclude VAT. VAT application depends on course format and your location:

  • Face-to-Face in Belgium: 21% Belgian VAT applies

  • Live online courses & self-study programme: The applicable VAT depends on your invoicing address. Contact your local VAT office for refund procedures where applicable.

 

TRANSFER & CANCELLATION POLICY

Flexible Transfer

If a registrant is unable to attend the scheduled course, they can avoid any cancellation charges by providing a suitable replacement participant.

Alternatively, the registrant may transfer once, on a 'space-available' basis and at no extra cost, to another course of the same value held within one year of the original course date, provided this is done at least three weeks prior to the event.

Registration Cancellation

  • Less than 14 days prior to the course date: The registrant is liable to pay the full invoiced registration fee.

  • Between 15 and 30 days prior to the course date: The registrant is liable to pay 50% of the invoiced registration fee.

  • More than 30 days prior to the course date: The registrant is liable to pay a cancellation fee of € 450 per registrant.

If a registrant postpones their participation to a future course and subsequently cancels again, no refund will be issued for the registration fees.
 

The average Recommendation Score from participants of the last session was 

9,5/10!

 

 

Testimonials from past participants:

This course fully lived up to my expectations—and more. I can't wait to put what we have learned into practice. Lieven is an excellent teacher.

LEO Pharma

Andreas Laursen, Global Pricing Principal - Denmark - March 2025

I encourage anyone without prior knowledge of HEOR to take this course. You’ll not only gain an awareness of the topic but also feel more confident participating in HEOR discussions.

Chiesi

Caterina Barone, Global Pricing Senior Analyst - Global - March 2025

A high-quality course that exceeded my expectations! Lieven managed to explain all the topics in a very pedagogical, easy-to-understand, and even fun way. Even though the course was intensive, I remained engaged throughout and was excited to bring back my learnings to discuss with my team.

Boehringer Ingelheim

Jemina Lehto, Oncology Medical Science Liaison, Nordics - The Netherlands - January 2025

Exceeded expectations – engaging, clear, and delivered with a varied teaching structure. Useful handout notes. Lots of practical examples to bring examples/models to life. Pitched at the right level and helped me feel more confident in health economics.

ViiV Healthcare

Gemma Barry, Market Access Manager - United Kingdom - January 2025

The mystery of health economics has now been unravelled! Two valuable days well invested, and I now feel confident in demonstrating the cost-effectiveness of this investment of my time – I may even illustrate it using a model! Thank you.

Convatec Group

Shona Macdonald, Director Market Access & Reimbursement UK - United Kingdom - January 2025

A very nice and well-delivered course!

GSK

Vesna Kolman, Global Marketing Manager - Belgium - January 2025

I participated in this training with Professor Lieven Annemans and I go home with a clear vision of health economics principles and some concrete follow-up actions to implement in my job. I recommend this training for every age/seniority/company size employee.

Sanofi

Margaux van Poucke, Issue Management & Patient Engagement Manager - Belgium - March 2024

I would highly recommend Lieven and this course. If you have the opportunity to go, you should! I feel a lot more confident and able to collaborate with my HE colleagues.

ViiV Healthcare

Lauren Mitchell, Market Access Manager - United Kingdom - March 2024

A great course bringing structure to the elements of Health Economics, allowing great understanding of the HE world. I can recommend the course for other marketing colleagues.

CSL Behring

Timothy Akroyd, Sr. Dir. Marketing Intercontinental Region - Switzerland - March 2024

The course is comprehensive, yet simple to follow and well-structured. Lieven has so much knowledge about Health Economics and really showed how you can apply everything practically.

Deciphera

Paolo Dametto, Director, EU Regulatory Affairs - Switzerland - March 2024

A very valuable course that provides a strong foundation in Health Economics. Makes me more confident about internal cross-functional engagement in the future.

GSK

Andy McGuffie, Government Affairs Director - United Kingdom - December 2023

Excellent content with enough details to provide the basics, but not too much to get annoyed if not in the field. The trainer motivates and engages everybody in the discussion and demonstrates in-depth knowledge of the topics. Organisation was great, from planning to attendance. In summary, this was an intense 2-day course of great value! I recommend attending this course to achieve better team work within cross-functional teams in the pharma industry!

Viatris

Laura Colombo, Global Medical Manager - Italy - October 2023

It was an enlightening experience. The brilliance in delivery by the seasoned health economics professor made complex topics easily digestible and engaging. The depth of each subject was precisely calibrated to our backgrounds, ensuring we left with both a comprehensive understanding and a sparked curiosity. For anyone seeking a solid foundation in health economics without being overwhelmed, this course is a beacon of excellence. Highly recommended!

ADVANZ Pharma

Dragos Mosneagu, Senior Manager in Portfolio Strategy - United Kingdom - October 2023

Couldn't recommend highly enough!

Pfizer

Margaret McDonnell, Market Access Director - Ireland - October 2023

Excellent course. Lieven Annemans made complicated models easy to understand.

Takeda

Birgitte Stroyer, Market Access Lead - Denmark - March 2023

My objective is fully met, namely to understand the basics, being able to calculate, understand and practice calculations (ICER, decision tree, etc). This allows me to become a better sparring partner internally and externally on HE-related topics and discussions.

Boehringer Ingelheim

Joey Dirker, Head of Go-To-Market Transformation Office - Germany - March 2023

Well-recommended courses. You can't find any better courses throughout the world.

MSD

Khaled Arman, Oncology Market Access Manager Jordan & Iran - Jordan - March 2023

Brilliant course design and content. Very relevant, I finished the course feeling like a HE specialist.

UCB

Sam Aldamee, Market Access Lead - United Kingdom - March 2023

A very concrete training with practical cases. Suitable for refreshing your knowledge or getting more insights.

Acticor

Adeline Meilhoc, Head of Global Clinical Development - France - March 2023

Great course that completely met my expectations. I really appreciated the discussions with Lieven and the group, the workshops (break-out sessions) were really useful and relevant.

Ferring

Mariia Tykhonova, Global Medical Training Manager, GMA Medical Excellence - France - December 2022

This course is a concise and well-structured introduction into Health Economics. It helped me to put my initial knowledge into context. In the future I will be able to discuss with Market Access and Pricing colleagues in a more targeted and qualified way. Thanks.

CSL Behring

Gunnar Philipp, Senior Director Medical Affairs - Switzerland - December 2022

Very knowledgeable expert and great added value. Would recommend and attend other courses. Also, very friendly and helpful staff.

Idorsia Pharmaceuticals

Inês Carreira Figueiredo, Medical Doctor, Medical Advisor - United Kingdom - December 2022

Excellent course by a highly professional expert.

MSD

Sherif Alam, Regional Marketing Director - United Arab Emirates - December 2022

Everything was very clearly explained in an engaging way.

Ferring

Kathryn Charlwood, Medical Communications Manager - Ireland - December 2022

Well organised, interactive, clear and meeting expectations: I recommend!

CSL Behring

Sandra Le Quellec, Director Medical Affairs Europe Gene Therapy/Hematology - France - December 2022

The programme is very well balanced in terms of topics, theory and examples and organisation of the course. The lecturer is brilliant. Thanks!

Novartis

Mariya Vladova, Innovative Market Access, Value and Data Insights Manager - Bulgaria - June 2022

Very comprehensive, yet practical and quick, introductory course into HEOR. Lieven is a knowledgeable, clear talker, enthusiastic about his field. Mixed audience in level of experience and companies, very nice. Thanks for everything, I enjoyed the training - it was very useful, nice and well organised.

Astellas

Olga Wedemeier, Sr. Medical Director BeNeLux - The Netherlands - June 2022

Lieven Annemans and his expertise made this a great course. I highly valued the examples from real life, the very clear theory and presentation and also the exercises. I really recommend this course.

Daiichi Sankyo

Pinar Özeken, Director Pricing & Value & Access Specialty Business Division Daiichi Sankyo Europe - Germany - June 2022

This training is a must for non-HE who want to develop further in HE.

GSK

Raymond Kienhuis, Field Market Access Manager - The Netherlands - June 2022

This training is a MUST for any professional new to the pharma sector. The big picture and key principles of Health Economics are presented in a comprehensive manner and are accompanied with many actionable insights.

Janssen

Jonathan Dicker, Manager Global Pricing Analytics - Belgium - December 2021

The course was very insightful. The expert knowledge of Lieven and his great way of disseminating his knowledge made the course very valuable. Although the course was mainly discussing examples from the pharmaceutical industry, the methods and general application of HE were easily understandable and could easily be transitioned to the medical technology industry as well. Anyone can easily follow the course and really gain sufficient knowledge and insight in HE evaluations, market access methodologies that can help companies improve their chances in achieving greater market access, and efficient ways to approach information and data gathering for amplifying the value of new technologies. Highly recommended!

MedTech Europe

Panagiotis Kokkinos, Digital Health Access Officer - Belgium - December 2021

Lieven really inspired me during this 2-day course.

Janssen

Rudy Taels, Business Intelligence Manager Neurosciences Benelux - The Netherlands - December 2021

A very complete, very insightful course that is useful to apply in a company setting. For me the online experience was excellent, no improvements needed. Thanks a lot to Lieven and to CELforPharma!

Roche

Christel Van-Weert, Head of Reputation Management - Belgium - June 2021

A very clear & concise course that was perfectly fitted to my level of understanding. Not too simple, not too advanced, with a nice balance of lectures and exercises. There was some really fun and constructive interaction within the group and it was interesting to hear from other countries' perspectives during group discussions. Many thanks to all involved!

Sanofi

Erland Marstein, Franchise Lead Immunology Norway - Norway - June 2021

This was a great opportunity to brush up on some skills and to interact with a knowledge expert in the field.

Novartis

Albert Hsu, Director, Global Market Access - Switzerland - March 2021

The HE course was absolutely excellent, pitched at the right level and helped me understand (and demystify!) this topic! There is an excellent balance between theory and practices with tangible real-life examples/illustrations. The trainer was excellent, showed huge expertise and was engaging! I strongly recommend this course!

Vertex Pharmaceuticals

Celine Ladure, International Marketing Director - United Kingdom - March 2021

I highly enjoyed the course. In only 2 days you get a great overview of HE and a couple of very pragmatic tools for how to think about issues in the field, as a layman. The theory becomes very tangible and applicable in everyday life.

Pfizer

Claire-Marie Rothlübbers, Sr Manager Market Access - Switzerland - March 2021

I just loved it! Great training, great teacher, perfectly managed by CELforPharma. It was a perfect mix of theory, group exercises, individual exercises, and discussions. These two days will provide you with all the needed tools to understand and challenge health economics models.

AbbVie

Jade Royers, Jade Royers, Market Access Value Proposition Manager - Belgium - March 2021

I have left the course with a lot more understanding of health economic evaluations, and the complexity in coming up with the data to inform payers and pharma companies in making decisions regarding treatment options. I plan to also follow the HTA course to see what the difference is and explore the possibility of specialising in this field.

Novo Nordisk

Monica Mirigo, Quality Assurance Specialist for Middle Africa - Kenya - March 2021

Very rich and intense experience taking this course. Would highly recommend to anyone looking to sharpen their knowledge and Health Economics understanding and its application in Pharma.

Novo Nordisk

Peter Mburu, Medical Advisor - Southern Africa - Kenya - March 2021

People attending this course are typically also interested in the below courses. 

Need help to find the right course? Email Inge Cornelis (Director, Client & Product Projects) or call +32 473 65 15 77

Do you want to upskill your team?

We can organise this training in-company (face-to-face or live online) and customise it to your specific focus and needs.

Fill in the below form and Inge Cornelis, Director of Client & Product Projects, will contact you with further information.
 

Course Details

Dates & Locations

7-8 October 2025

Brussels

Register

25-26 November 2025

Brussels

Register

Dates don't suit? Check out our Online Self-study Programme Basics of Health Economics.

Upcoming Session

7-8 October 2025, Brussels

Early bird € 2 970

(until 22/08/2025)

 (Full fee € 3 370)

Prices are excl. VAT

Pharma/medtech products cannot be successful without a favourable cost-effectiveness and budget impact profile.

Therefore, all managers in clinical development, regulatory, market access (and related), medical affairs, and marketing should understand the fundamentals of health economic evaluations and budget impact analysis.

Only then will they take product-related decisions that consider the payers’ perspectives and optimally communicate value to payers, KOLs and other external stakeholders.

Upon completion of this course, you will master the fundamentals of health economic evaluations as a non-health-economist. And you will be able to add value to decisions and communications related to products in R&D and/or brands in the market.

By participating, you will not only have the chance to learn from a renowned expert, but also experience the unique opportunity to share experiences and engage in in-depth discussions with your international peers. 
 

Hear directly from Lieven why you should attend this course:

I encourage anyone without prior knowledge of HEOR to take this course. You’ll not only gain an awareness of the topic but also feel more confident participating in HEOR discussions.

Chiesi

Caterina Barone, Global Pricing Senior Analyst - Global - March 2025

  1. The logic and mathematics behind QALYs, ICERs, decision trees and Markov models.

  2. How external stakeholders use and challenge health economic evidence.

  3. How to distinguish good from bad health economic evaluation studies (of your brand or its competitors).

  4. Key principles of cost-effectiveness analysis and Budget Impact Analysis.

  5. The role of health economic evaluations in clinical research, pricing & reimbursement decisions, and post-launch. 

Course agenda

 

The mystery of health economics has now been unravelled! Two valuable days well invested, and I now feel confident in demonstrating the cost-effectiveness of this investment of my time – I may even illustrate it using a model! Thank you.

Convatec Group

Shona Macdonald, Director Market Access & Reimbursement UK - United Kingdom - January 2025

 

 

Day 1
10:00Welcome & General Introduction
10:30Fundamentals of Health Economic Evaluations: QALY - ICER - HTA
 
  • Why health economic evaluations are necessary
  • Key principles of health economic evaluations
    • QALY: The mathematics – examples
    • Value for money: Balancing costs vs. health effect
    • The Incremental Cost-Effectiveness Ratio (ICER) and the thresholds determined by payers
    • Health economic evaluations vs. Health Technology Assessment (HTA)
11:45Coffee Break
12:00Health Economic Modelling – Commonly Used Models
 
  • Decision Trees
    • The logic of this model will first be explained with a simplified example
    • Real-world examples
  • Markov models
    • The logic of this model will first be explained with a simplified example
    • Real-world examples
  • Example of a Discrete Event Simulation
  • How to make models credible and reliable
  • When to use which model
13:15Lunch Break
14:00Cost Analysis and Budget Impact Analysis: Key Principles
 
  • The perspective of the study: Societal – Health Care Sector – Hospital
  • Impact of the perspective on costs and savings
  • How to deal with current benefits versus benefits in the future?
  • Budget Impact Analysis: Answering the question of affordability
15:30Coffee Break
15:45Prospective Research for Health Economic Evaluations (Includes a Group Exercise)
 
  • Conflicts between the clinical and the health economic perspective
  • Six practical steps for prospective “within-trial” health economic studies
  • Break-Out Session: “To HE or not to HE?”: Participants will discuss in groups the pros and cons of collecting health economic (HE) data directly into a phase III trial in the field of asthma.
  • Addressing the challenges of integrating clinical data in health economic evaluations
17:00Close Day 1
 
Day 2
09:00Recap of Day 1 With Exercises on QALYs & ICERs
09:45Guidelines for Health Economic Evaluations (Includes a Group Exercise)
 
  • What distinguishes a good from a poor health economic evaluation?
  • A 10-item checklist for a good health economic paper
  • How to increase the credibility of health economic messages in the value message?
  • Break-Out Session: In groups, participants will assess a health economic evaluation that has been shared as a pre-read using the 10-item checklist. Findings will be discussed in plenary. 
10:30Coffee Break
10:45Guidelines for Health Economic Evaluations (continued)
12:30Lunch Break
13:15Use of Health Economic Evaluations in Price & Reimbursement Decision Making
 
  • What is true innovation – the payer perspective
  • The secrets behind measuring the QALY and its limitations
  • The role of medical need
  • The role of budget impact
  • Dealing with uncertainty: Outcome-based managed entry agreements
14:30Health Economic Evaluations in a Pharmaceutical Drug’s Life Cycle
 
  • The importance and purpose of early economic models
  • Organisation and processes within HQ and affiliates
  • Post-launch and the use of real-world data
15:00Break-Out Session: Developing Together a Health Economic Strategy
 In groups, participants will design an early decision model (a decision tree) for a new medicine. They will assess which key pre-marketing data are needed to complete the health economic value story and how these data can be collected.
Group findings will be discussed in plenary.
Coffee Break will be served during break-out session
16:00Final Discussion
16:15End of Course

 

Download Brochure

 

What is the difference with the Online Self-study Programme Basics of Health Economics?

  • The 2-day face-to-face course has more breadth and depth in both theory (lectures) and practice (group work). For instance, the 2-hour module on the “Guidelines for Health Economic Evaluations” is highly valued because of the interactive group work session on a health economic publication.

  • In a face-to-face classroom training, you learn a lot from your industry peers because of the exchange of experiences and ideas and the discussions about issues you face in your function. The Q&A sessions are very rich and you will have many opportunities for conversations with your peers outside the formal programme. 

  • Participating in the 2-day course gives the opportunity to meet Prof. Dr Lieven Annemans and discuss your own projects/issues with him during the breaks. 

Complete the below form to download the full course brochure. It outlines the detailed agenda, learning outcomes, expert info and some testimonials from past participants.

  • Prof. Dr Lieven Annemans has participated in more than 400 health economic evaluations in over 20 countries across a wide spectrum of therapeutic areas. He has also been involved as an expert in a large number of Health Technology Assessments (HTAs) and is actively involved in HTA on a European level.

  • Lieven has a unique profile: academic professor, past-president of ISPOR, author of Health economics for non-economists (Pelckmans Pro, 2018), trainer and consultant.

  • Highly respected for his vast international and cross-therapeutic experience, Lieven is a sought-after advisor and educator to health policy makers and the innovative healthcare industry.

  • Lieven has been on CELforPharma's faculty since 2009 and is always applauded by participants for his engaging and fun teaching style.
     

This course fully lived up to my expectations—and more. I can't wait to put what we have learned into practice. Lieven is an excellent teacher.

LEO Pharma

Andreas Laursen, Global Pricing Principal - Denmark - March 2025

As the course title suggests, this course is designed for non-health-economists.

As pharma companies are facing ever-increasing hurdles to optimise market access for their brands, all managers in product development, medical affairs and marketing should attend this course so that they can contribute to a successful integration of health economic evaluations into clinical, medical and brand plans.

While most of the examples and exercises discussed in this course are about pharmaceuticals, this course is equally relevant to, and has always been highly valued by, executives from the medical devices industry.

Would you like to receive a list of anonymised participant profiles from previous sessions? 

Email Annelies Swaan

 

 

UPCOMING DATES & FORMATS - FEES

7-8 October 2025

Brussels

Early bird € 2 970

(until 22/08/2025)

(Full fee € 3 370)

25-26 November 2025

Brussels

Early bird € 2 970

(until 10/10/2025)

(Full fee € 3 370)

 

Dates don't suit or you do not have the possibility to travel to Brussels?

Check out our Online Self-Study Programme Basics of Health Economics with Prof. Dr Lieven Annemans.

 


TIMING & LOCATION

  • Live Online (CET): Zoom sessions between 9 AM and 5 PM CET (Brussels, Amsterdam, Paris time).

  • Live Online (EST): Zoom sessions between 8 AM and 4 PM EST (Eastern Standard Time).

  • Face-to-Face: Held at the Crowne Plaza Brussels Airport (Da Vincilaan 4, 1831 Brussels), between 9 AM and 5 PM CET. Preferential hotel rates available for participants.

All practical details will be shared upon registration. For any questions, please contact Margherita Mutto or call +32 472 03 11 38 .

 

GROUP DISCOUNTS

Team discounts can be offered to 2 or more delegates from the same company.

Email Annelies Swaan, Director Business Operations, for more details. 

 

HOW TO REGISTER

  • Click the green “Register” button on your preferred course session.
    The registration wizard will guide you through the process.

  • Alternatively, download the offline registration form and send the completed form to Annelies Swaan.

 

PAYMENT OPTIONS

  • Credit Card: You’ll receive a secure payment link with your invoice (no immediate payment required).

  • Bank Transfer: Details provided with your invoice.

For help with registration, email Annelies Swaan or contact her by phone at +32 486 98 52 49.

 

INCLUDED IN THE REGISTRATION FEE

  • Access to a highly interactive, small-group course (max 20 participants)

  • Course materials in both digital and hard copy format

  • Certificate of attendance signed by the experts and CELforPharma

  • Opportunities for networking and informal discussions during coffee/tea breaks and lunch

  • A group dinner in a nearby restaurant on the evening of day 1

 

VAT INFORMATION

Prices exclude VAT. VAT application depends on course format and your location:

  • Face-to-Face in Belgium: 21% Belgian VAT applies

  • Live online courses & self-study programme: The applicable VAT depends on your invoicing address. Contact your local VAT office for refund procedures where applicable.

 

TRANSFER & CANCELLATION POLICY

Flexible Transfer

If a registrant is unable to attend the scheduled course, they can avoid any cancellation charges by providing a suitable replacement participant.

Alternatively, the registrant may transfer once, on a 'space-available' basis and at no extra cost, to another course of the same value held within one year of the original course date, provided this is done at least three weeks prior to the event.

Registration Cancellation

  • Less than 14 days prior to the course date: The registrant is liable to pay the full invoiced registration fee.

  • Between 15 and 30 days prior to the course date: The registrant is liable to pay 50% of the invoiced registration fee.

  • More than 30 days prior to the course date: The registrant is liable to pay a cancellation fee of € 450 per registrant.

If a registrant postpones their participation to a future course and subsequently cancels again, no refund will be issued for the registration fees.
 

The average Recommendation Score from participants of the last session was 

9,5/10!

 

 

Testimonials from past participants:

This course fully lived up to my expectations—and more. I can't wait to put what we have learned into practice. Lieven is an excellent teacher.

LEO Pharma

Andreas Laursen, Global Pricing Principal - Denmark - March 2025

I encourage anyone without prior knowledge of HEOR to take this course. You’ll not only gain an awareness of the topic but also feel more confident participating in HEOR discussions.

Chiesi

Caterina Barone, Global Pricing Senior Analyst - Global - March 2025

A high-quality course that exceeded my expectations! Lieven managed to explain all the topics in a very pedagogical, easy-to-understand, and even fun way. Even though the course was intensive, I remained engaged throughout and was excited to bring back my learnings to discuss with my team.

Boehringer Ingelheim

Jemina Lehto, Oncology Medical Science Liaison, Nordics - The Netherlands - January 2025

Exceeded expectations – engaging, clear, and delivered with a varied teaching structure. Useful handout notes. Lots of practical examples to bring examples/models to life. Pitched at the right level and helped me feel more confident in health economics.

ViiV Healthcare

Gemma Barry, Market Access Manager - United Kingdom - January 2025

The mystery of health economics has now been unravelled! Two valuable days well invested, and I now feel confident in demonstrating the cost-effectiveness of this investment of my time – I may even illustrate it using a model! Thank you.

Convatec Group

Shona Macdonald, Director Market Access & Reimbursement UK - United Kingdom - January 2025

A very nice and well-delivered course!

GSK

Vesna Kolman, Global Marketing Manager - Belgium - January 2025

I participated in this training with Professor Lieven Annemans and I go home with a clear vision of health economics principles and some concrete follow-up actions to implement in my job. I recommend this training for every age/seniority/company size employee.

Sanofi

Margaux van Poucke, Issue Management & Patient Engagement Manager - Belgium - March 2024

I would highly recommend Lieven and this course. If you have the opportunity to go, you should! I feel a lot more confident and able to collaborate with my HE colleagues.

ViiV Healthcare

Lauren Mitchell, Market Access Manager - United Kingdom - March 2024

A great course bringing structure to the elements of Health Economics, allowing great understanding of the HE world. I can recommend the course for other marketing colleagues.

CSL Behring

Timothy Akroyd, Sr. Dir. Marketing Intercontinental Region - Switzerland - March 2024

The course is comprehensive, yet simple to follow and well-structured. Lieven has so much knowledge about Health Economics and really showed how you can apply everything practically.

Deciphera

Paolo Dametto, Director, EU Regulatory Affairs - Switzerland - March 2024

A very valuable course that provides a strong foundation in Health Economics. Makes me more confident about internal cross-functional engagement in the future.

GSK

Andy McGuffie, Government Affairs Director - United Kingdom - December 2023

Excellent content with enough details to provide the basics, but not too much to get annoyed if not in the field. The trainer motivates and engages everybody in the discussion and demonstrates in-depth knowledge of the topics. Organisation was great, from planning to attendance. In summary, this was an intense 2-day course of great value! I recommend attending this course to achieve better team work within cross-functional teams in the pharma industry!

Viatris

Laura Colombo, Global Medical Manager - Italy - October 2023

It was an enlightening experience. The brilliance in delivery by the seasoned health economics professor made complex topics easily digestible and engaging. The depth of each subject was precisely calibrated to our backgrounds, ensuring we left with both a comprehensive understanding and a sparked curiosity. For anyone seeking a solid foundation in health economics without being overwhelmed, this course is a beacon of excellence. Highly recommended!

ADVANZ Pharma

Dragos Mosneagu, Senior Manager in Portfolio Strategy - United Kingdom - October 2023

Couldn't recommend highly enough!

Pfizer

Margaret McDonnell, Market Access Director - Ireland - October 2023

Excellent course. Lieven Annemans made complicated models easy to understand.

Takeda

Birgitte Stroyer, Market Access Lead - Denmark - March 2023

My objective is fully met, namely to understand the basics, being able to calculate, understand and practice calculations (ICER, decision tree, etc). This allows me to become a better sparring partner internally and externally on HE-related topics and discussions.

Boehringer Ingelheim

Joey Dirker, Head of Go-To-Market Transformation Office - Germany - March 2023

Well-recommended courses. You can't find any better courses throughout the world.

MSD

Khaled Arman, Oncology Market Access Manager Jordan & Iran - Jordan - March 2023

Brilliant course design and content. Very relevant, I finished the course feeling like a HE specialist.

UCB

Sam Aldamee, Market Access Lead - United Kingdom - March 2023

A very concrete training with practical cases. Suitable for refreshing your knowledge or getting more insights.

Acticor

Adeline Meilhoc, Head of Global Clinical Development - France - March 2023

Great course that completely met my expectations. I really appreciated the discussions with Lieven and the group, the workshops (break-out sessions) were really useful and relevant.

Ferring

Mariia Tykhonova, Global Medical Training Manager, GMA Medical Excellence - France - December 2022

This course is a concise and well-structured introduction into Health Economics. It helped me to put my initial knowledge into context. In the future I will be able to discuss with Market Access and Pricing colleagues in a more targeted and qualified way. Thanks.

CSL Behring

Gunnar Philipp, Senior Director Medical Affairs - Switzerland - December 2022

Very knowledgeable expert and great added value. Would recommend and attend other courses. Also, very friendly and helpful staff.

Idorsia Pharmaceuticals

Inês Carreira Figueiredo, Medical Doctor, Medical Advisor - United Kingdom - December 2022

Excellent course by a highly professional expert.

MSD

Sherif Alam, Regional Marketing Director - United Arab Emirates - December 2022

Everything was very clearly explained in an engaging way.

Ferring

Kathryn Charlwood, Medical Communications Manager - Ireland - December 2022

Well organised, interactive, clear and meeting expectations: I recommend!

CSL Behring

Sandra Le Quellec, Director Medical Affairs Europe Gene Therapy/Hematology - France - December 2022

The programme is very well balanced in terms of topics, theory and examples and organisation of the course. The lecturer is brilliant. Thanks!

Novartis

Mariya Vladova, Innovative Market Access, Value and Data Insights Manager - Bulgaria - June 2022

Very comprehensive, yet practical and quick, introductory course into HEOR. Lieven is a knowledgeable, clear talker, enthusiastic about his field. Mixed audience in level of experience and companies, very nice. Thanks for everything, I enjoyed the training - it was very useful, nice and well organised.

Astellas

Olga Wedemeier, Sr. Medical Director BeNeLux - The Netherlands - June 2022

Lieven Annemans and his expertise made this a great course. I highly valued the examples from real life, the very clear theory and presentation and also the exercises. I really recommend this course.

Daiichi Sankyo

Pinar Özeken, Director Pricing & Value & Access Specialty Business Division Daiichi Sankyo Europe - Germany - June 2022

This training is a must for non-HE who want to develop further in HE.

GSK

Raymond Kienhuis, Field Market Access Manager - The Netherlands - June 2022

This training is a MUST for any professional new to the pharma sector. The big picture and key principles of Health Economics are presented in a comprehensive manner and are accompanied with many actionable insights.

Janssen

Jonathan Dicker, Manager Global Pricing Analytics - Belgium - December 2021

The course was very insightful. The expert knowledge of Lieven and his great way of disseminating his knowledge made the course very valuable. Although the course was mainly discussing examples from the pharmaceutical industry, the methods and general application of HE were easily understandable and could easily be transitioned to the medical technology industry as well. Anyone can easily follow the course and really gain sufficient knowledge and insight in HE evaluations, market access methodologies that can help companies improve their chances in achieving greater market access, and efficient ways to approach information and data gathering for amplifying the value of new technologies. Highly recommended!

MedTech Europe

Panagiotis Kokkinos, Digital Health Access Officer - Belgium - December 2021

Lieven really inspired me during this 2-day course.

Janssen

Rudy Taels, Business Intelligence Manager Neurosciences Benelux - The Netherlands - December 2021

A very complete, very insightful course that is useful to apply in a company setting. For me the online experience was excellent, no improvements needed. Thanks a lot to Lieven and to CELforPharma!

Roche

Christel Van-Weert, Head of Reputation Management - Belgium - June 2021

A very clear & concise course that was perfectly fitted to my level of understanding. Not too simple, not too advanced, with a nice balance of lectures and exercises. There was some really fun and constructive interaction within the group and it was interesting to hear from other countries' perspectives during group discussions. Many thanks to all involved!

Sanofi

Erland Marstein, Franchise Lead Immunology Norway - Norway - June 2021

This was a great opportunity to brush up on some skills and to interact with a knowledge expert in the field.

Novartis

Albert Hsu, Director, Global Market Access - Switzerland - March 2021

The HE course was absolutely excellent, pitched at the right level and helped me understand (and demystify!) this topic! There is an excellent balance between theory and practices with tangible real-life examples/illustrations. The trainer was excellent, showed huge expertise and was engaging! I strongly recommend this course!

Vertex Pharmaceuticals

Celine Ladure, International Marketing Director - United Kingdom - March 2021

I highly enjoyed the course. In only 2 days you get a great overview of HE and a couple of very pragmatic tools for how to think about issues in the field, as a layman. The theory becomes very tangible and applicable in everyday life.

Pfizer

Claire-Marie Rothlübbers, Sr Manager Market Access - Switzerland - March 2021

I just loved it! Great training, great teacher, perfectly managed by CELforPharma. It was a perfect mix of theory, group exercises, individual exercises, and discussions. These two days will provide you with all the needed tools to understand and challenge health economics models.

AbbVie

Jade Royers, Jade Royers, Market Access Value Proposition Manager - Belgium - March 2021

I have left the course with a lot more understanding of health economic evaluations, and the complexity in coming up with the data to inform payers and pharma companies in making decisions regarding treatment options. I plan to also follow the HTA course to see what the difference is and explore the possibility of specialising in this field.

Novo Nordisk

Monica Mirigo, Quality Assurance Specialist for Middle Africa - Kenya - March 2021

Very rich and intense experience taking this course. Would highly recommend to anyone looking to sharpen their knowledge and Health Economics understanding and its application in Pharma.

Novo Nordisk

Peter Mburu, Medical Advisor - Southern Africa - Kenya - March 2021

Do you want to upskill your team?

We can organise this training in-company (face-to-face or live online) and customise it to your specific focus and needs.

Fill in the below form and Inge Cornelis, Director of Client & Product Projects, will contact you with further information.
 

Dates & Locations

7-8 October 2025

Brussels

Register

25-26 November 2025

Brussels

Register

Dates don't suit? Check out our Online Self-study Programme Basics of Health Economics.